Section Editor: Trevor Flood MD FRCPC
October 22, 2026
Seminoma is a type of cancer that starts in the testicle. It is the most common testicular cancer in adults. Seminoma belongs to a group of cancers called germ cell tumors, which develop from the cells that normally produce sperm. Most seminomas are found while the cancer is still limited to the testicle, and seminoma is one of the most curable cancers in adults.
This article explains what seminoma is, how the diagnosis is made after the testicle is removed, and what the measurements in your seminoma pathology report mean. It also explains the pathologic stage and how your report’s findings shape the next steps in your care.
Seminoma most often affects men between 25 and 45, peaking in the 30s. That is about ten years later than most other testicular germ cell tumors. Seminoma is rare in children and uncommon after age 60. About half of all testicular germ cell tumors are seminomas.
Seminoma develops from an early change in the testicle called germ cell neoplasia in situ, or GCNIS. In GCNIS, abnormal germ cells grow inside the small tubes of the testicle where sperm are made. These tubes are called seminiferous tubules, and they make up most of the testicle. When abnormal cells break out of the tubules into the surrounding tissue, they can form an invasive germ cell tumor, such as seminoma.
GCNIS is thought to begin before birth, while the testicles are developing. Why it later turns into cancer in some men is not fully understood. Factors that increase the risk of seminoma include:
The most common symptom of seminoma is a painless lump or swelling in one testicle. Some men notice heaviness in the scrotum or a dull ache in the lower abdomen. A few men have pain or tenderness in the testicle. When seminoma spreads to the lymph nodes in the back of the abdomen, it can cause back pain. Some seminomas are found during tests for another reason, such as an ultrasound for infertility.
The diagnosis of seminoma usually begins with a scrotal ultrasound, which shows a solid mass inside the testicle. Blood tests for tumor markers are also done before surgery, because some testicular tumors release these substances into the blood. A needle biopsy of the testicle is rarely performed. Instead, the whole testicle is removed through a cut in the groin in an operation called a radical orchiectomy. The surgery removes the testicle together with part of the spermatic cord, which carries the blood vessels and the tube for sperm.
A pathologist then examines the testicle first with the naked eye, then under the microscope. Seminoma consists of sheets of large, round tumor cells with clear cytoplasm. Thin bands of tissue containing many lymphocytes, a type of immune cell, divide the cells into groups. Small clusters of immune cells called granulomas are often present.
The pathologist also checks every part of the tumor for other types of germ cell tumor. If any other type is found, the tumor is not a pure seminoma. It is then called a mixed germ cell tumor, which is treated differently. Seminoma also differs from spermatocytic tumor, once called spermatocytic seminoma. Spermatocytic tumor affects older men, does not arise from GCNIS, and rarely spreads.
Some seminomas contain scattered large cells called syncytiotrophoblasts, which produce the hormone hCG. These cells can raise blood hCG levels. Your report may describe this as seminoma with syncytiotrophoblastic cells. This finding does not change the diagnosis of seminoma or its outlook.
Once seminoma is confirmed, a CT scan of the abdomen, pelvis, and chest checks whether the cancer has spread to lymph nodes or other organs. Your pathologist may also have used special stains to confirm the diagnosis, which are described in the next section.
Immunohistochemistry uses antibodies to show which proteins tumor cells make. In seminoma, pathologists use immunohistochemistry to confirm the diagnosis and to separate seminoma from other germ cell tumors, which are treated differently. The stains used vary between laboratories, but typical results in seminoma include:
Not every seminoma needs all these stains, and when the tumor looks typical under the microscope, pathologists may use only a few.
Tumor markers are substances in the blood that some germ cell tumors release. For seminoma, the three markers tested are alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and lactate dehydrogenase (LDH). We measure them before orchiectomy and again after. These results are reported separately from the pathology report, but they work together with it.
We use marker levels measured after surgery to assign the S category in staging, described below. Our article on tumor markers in your blood test explains these tests in more detail.
Unlike many other cancers, seminoma is not given a histologic grade. Grade describes how different cancer cells look from normal cells, and many other cancers are graded to predict behavior. Seminoma cells look very similar from one tumor to the next, so grading adds no useful information. Your seminoma pathology report will not include a grade, as expected.
The pathologist measures the seminoma in the removed testicle and reports its greatest dimension in centimeters. If there is more than one tumor nodule, the pathologist usually measures the largest and lists the others separately.
Tumor size matters for two reasons in seminoma. First, size divides stage pT1 seminoma into pT1a (smaller than 3 cm) and pT1b (3 cm or larger). Second, a seminoma larger than 4 cm has a higher chance of coming back after surgery when no further treatment is given. Your care team uses the size to discuss options after surgery.
The rete testis is a network of small channels near the top of the testicle that collects sperm before it moves into the epididymis. Rete testis invasion means seminoma cells have grown into the tissue around these channels. Your report will say whether rete testis invasion is present or not identified.
Rete testis invasion does not change the pathologic stage of seminoma. However, it is linked with a higher chance that the cancer will come back after surgery alone. Together with tumor size larger than 4 cm, it helps your team estimate your risk of relapse. Sometimes abnormal GCNIS cells spread along the lining of the channels without invading the surrounding tissue. This is called pagetoid spread, and it is not counted as rete testis invasion.
Tumor extension describes how far the seminoma has grown beyond the testicle, although most seminomas stay within it. The pathologist examines the nearby tissues to see whether tumor cells have reached any of these structures:
Growth into any of these structures increases the tumor stage (pT). Growth into the tunica albuginea, the tough capsule directly around the testicle, does not raise the stage on its own.
Lymphovascular invasion means seminoma cells were seen inside a blood vessel or lymphatic channel. These vessels carry blood and fluid away from the testicle, so tumor cells inside them can spread to lymph nodes or other organs. Your report will describe lymphovascular invasion as present, not identified, or cannot be determined.
In seminoma, lymphovascular invasion changes the stage, so always report it. A tumor limited to the testicle is pT1 without lymphovascular invasion but pT2 with it.
Germ cell neoplasia in situ, or GCNIS, is the early change that can develop into seminoma. In GCNIS, abnormal germ cells line the seminiferous tubules but have not broken out into the surrounding tissue. GCNIS is found in the testicle next to most seminomas.
Your report may mention GCNIS in the tissue around the tumor. This is an expected finding and does not change the stage, because the invasive seminoma already sets the stage. If GCNIS is the only change found in a testicle, stage it as pTis.
Sometimes a seminoma shrinks or disappears inside the testicle before surgery, leaving only a scar, in a process called regression. Your report may describe a scar, fibrosis, or a regressed germ cell tumor. The pathologist makes this diagnosis when the scar contains GCNIS or coarse calcifications inside the tubules.
A regressed tumor matters most when cancer has been found elsewhere in the body, such as in lymph nodes at the back of the abdomen. In that situation, the scar shows that the cancer most likely started in the testicle.
A margin is the cut edge of tissue removed during surgery. After a radical orchiectomy for seminoma, the most important margin is the end of the spermatic cord, which is the last tissue cut by the surgeon. Your report will describe the margins in one of these ways:
When only part of the testicle has been removed, in an operation called a partial orchiectomy, the report also describes the margin in the remaining testicle.
Lymph nodes are small immune organs found throughout the body. Seminoma usually spreads first to the retroperitoneal lymph nodes at the back of the abdomen. These nodes are not removed during a radical orchiectomy, so most seminoma pathology reports from orchiectomy do not include any lymph nodes.
When lymph nodes are removed in a later operation called a retroperitoneal lymph node dissection, the pathologist reports:
A lymph node described as negative contains no cancer cells, while a lymph node described as positive contains seminoma cells.
Seminoma pathologic stage is based on the tumor in the removed testicle (pT) and any lymph nodes examined (pN). It uses the TNM staging system in the 8th edition of the AJCC Cancer Staging Manual, which the current CAP testis protocol uses. Spread to distant organs (M) is usually determined by imaging, not by the pathologist.
Sometimes seminoma cells are found in the spermatic cord, separate from the main tumor, carried there in a blood vessel. Under the AJCC 8th edition, this is treated as a deposit of spread cancer and staged as pM1, not pT3. Older reports written under the 7th edition staged this finding as pT3.
The overall seminoma stage group does not match the pathologic stage in your report. Your care team assigns the stage group by combining the pathology findings, the CT scans, and the blood tumor markers (the S category, from S0 to S3). In broad terms, the stage groups are:
The prognosis for seminoma is excellent, even when it has spread. About 3 in 4 people with seminoma have stage I disease at diagnosis. For stage I seminoma, more than 99 in 100 people are cured.
After surgery alone, about 12 to 20 in 100 people with stage I seminoma have the cancer come back. Most relapses appear in the lymph nodes at the back of the abdomen. That means about 4 in 5 never need further treatment. When the cancer does come back, it is almost always caught by regular scans and cured with further treatment. The relapse rate is lower for small tumors without rete testis invasion. It is higher when the tumor is larger than 4 cm or invades the rete testis. When both features are present, some studies report relapse in about 20 to 30 in 100 people.
Seminoma that has spread beyond the testicle is also very often curable; for stage IIA and IIB seminoma treated with chemotherapy, about 99 in 100 people survive. For seminoma that has spread more widely, an international system called IGCCCG, updated in 2021, divides people into two groups:
Pathologic features on your seminoma report that are linked with a higher chance of the cancer spreading or coming back include:
After seminoma is confirmed on the orchiectomy specimen, the next steps depend mainly on the stage group. Tumor size and rete testis invasion also matter for stage I seminoma. A team that includes a urologist, a medical oncologist, and a radiation oncologist usually plans care.
For stage I seminoma, the options your team may discuss include:
For seminoma that has spread to lymph nodes or other organs, treatment usually involves chemotherapy combinations that include cisplatin. Radiation therapy may be considered for smaller lymph node deposits. Some specialized centers also offer surgery to remove lymph nodes for low-volume stage II seminoma, often as part of a clinical trial. The IGCCCG prognosis group helps your team decide how much chemotherapy is needed.
Removing one testicle usually does not affect fertility or hormone levels because the other testicle continues to work. Chemotherapy and radiation can lower sperm production, so sperm banking is usually discussed before any further treatment. Some men choose a testicular prosthesis, which can be placed during the orchiectomy or later. Follow-up visits continue for several years and include checks of testosterone and of the remaining testicle.
🔍 Search MyPathologyReport
Type what you see on your report — for example a diagnosis or test name